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http://dx.doi.org/10.1016/j.stemcr.2016.05.005SUMMARYHuman pluripotent stem cells (hPSCs) provide an unlimited cell source for regenerative medicine. Hormone-producing cells are partic-
ularly suitable for cell therapy, and hypopituitarism, a defect in pituitary gland function, represents a promising therapeutic target. Pre-
vious studies have derived pituitary lineages from mouse and human ESCs using 3D organoid cultures that mimic the complex events
underlying pituitary gland development in vivo. Instead of relying on unknowncellular signals, we present a simple and efficient strategy
to derive human pituitary lineages fromhPSCs usingmonolayer culture conditions suitable for cell manufacturing.We demonstrate that
purified placode cells can be directed into pituitary fates using defined signals. hPSC-derived pituitary cells show basal and stimulus-
induced hormone release in vitro and engraftment and hormone release in vivo after transplantation into a murine model of hypopitu-
itarism. This work lays the foundation for future cell therapy applications in patients with hypopituitarism.INTRODUCTION
Human pluripotent stem cells (hPSCs) provide a unique
resource for basic as well as translational research. Both hu-
man embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs) are widely used to study
early human development (Zhu and Huangfu, 2013),
assess the toxic effects of chemicals (Dreser et al., 2015;
Zimmer et al., 2012), model human diseases or cancer (Bel-
lin et al., 2012; Funato et al., 2014; Merkle and Eggan,
2013), and discover novel potential drugs (Lee et al.,
2012). Furthermore, access to greatly improved protocols
for lineage-specific differentiation has led to the first
experimental applications of hPSC-derived lineages in
regenerative medicine such as in patients with macular
degeneration (Schwartz et al., 2015). Other hPSC-based
applications that are being pursued intensely include
the replacement of hormone-producing cells such as
in type 1 diabetes (Pagliuca et al., 2014; Rezania et al.,
2014). Replacing hormone-producing cells is a particularly
attractive approach for cell therapy, especially if restoration
of feedback mechanisms with subsequent dynamic release
of hormones can be achieved by the grafted cells.
The pituitary gland is considered themaster gland of hor-
mone function. Hypopituitarism is a disease condition
with insufficient or absent function of the pituitary gland.
Pituitary tumors are the most common cause but many
other triggers can induce pituitary dysfunction including
inborn genetic defects, brain trauma, immune and infec-
tious diseases, or radiation therapy. The prevalence of hy-858 Stem Cell Reports j Vol. 6 j 858–872 j June 14, 2016 j ª 2016 The Autho
This is an open access article under the CC BY license (http://creativecommopopituitarism has been estimated at 46 per 100,000 (Regal
et al., 2001), but this is likely an underestimation. The con-
sequences of pituitary dysfunction are particularly serious
in children where they can lead to severe learning disabil-
ities, growth and skeletal problems, as well as effects
on puberty and sexual function (Chemaitilly and Sklar,
2010). Chronic hypopituitarism requires lifelong complex
hormone replacement therapies that are very costly and
compromise quality of life. Furthermore, static delivery of
hormones can only poorly mimic the dynamic secretion
of the intact pituitary gland, which reacts to feedback
mechanisms such as the hypothalamic-pituitary-adrenal
(HPA) axis or the circadian clock. Therefore, there is a
considerable clinical need to direct current treatment para-
digms toward amore physiological and complete hormone
replacement therapy (Smith, 2004).
It is conceivable that replacing the damaged cells via cell
transplantation can restore pituitary function and perma-
nently cure chronic hypopituitarism. Previous work in
mouse ESCs has shown that anterior pituitary cells, capable
of hormone secretion, can be generated in 3D cultures by
recapitulating some of the complex morphogenetic inter-
action between the developing hypothalamic and oral
ectoderm tissues in vitro (Suga et al., 2011). Our laboratory
has recently reported a first attempt at generating func-
tional adenohypophyseal cells from human PSCs (Dincer
et al., 2013), and very recently pituitary cells have been
generated from hPSCs using a 3D organoid approach
(Ozone et al., 2016). While these studies represent a
promising proof of concept, current protocols remainrs.
ns.org/licenses/by/4.0/).
Figure 1. Differentiation of hPSCs into Cranial Placode Using Chemically Defined Conditions
(A) Schematic representation of cranial placode in vivo development and protocol for directed differentiation of hPSCs. ICM, inner
cell mass.
(B) Real-time PCR gene expression time course of key cranial placode (SIX1, EYA1) and non-neural ectoderm (TFAP2A, DLX3/5, GATA3)
genes as well as genes probing for potential contaminates (SOX10, T, SOX17, MYOD). Values are normalized to GAPDH and expression on
(legend continued on next page)
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inefficient, poorly defined, and unsuitable for developing
current good manufacturing practice (cGMP)-compatible
culture conditions that will be eventually required for hu-
man therapeutic use.
Here, we report the efficient derivation of anterior pitui-
tary cells from hPSCs in clinically compatible and scalable
culture conditions. We further characterize the diversity of
anterior pituitary subtypes achieved in vitro using single-
cell mRNA expression analysis. The resulting hPSC-derived
pituitary cells are functional in vitro, respond to appro-
priate stimuli, and are capable of secreting hormones in
an animal model of hypopituitarism in vivo. Importantly,
our data indicate that pituitary cell fate can be induced in-
dependent of mimicking the complex 3D organization of
the developing gland. We demonstrate that by providing
appropriate signals to purified placode precursor cells, pitu-
itary identity can be specified at high efficiency, and that
further manipulations of morphogen gradients enable
controlled changes in the relative composition of hor-
monal cell types. In conclusion, we provide a robust differ-
entiation platform to access diverse hormone-producing
cell types suitable for further development toward a cell-
based treatment of hypopituitarism.RESULTS
Derivation of Cranial Placode from hPSCs under Fully
Defined Conditions
The anterior pituitary gland is derived from cranial placode
cells that form from the oral ectoderm. Therefore, the first
step in establishing a defined protocol is the efficient in-
duction of cranial placode cells competent in generating
anterior pituitary lineages. The cranial placode induction
protocol (PIP) presented here relies on serum-free mono-
layer-based induction conditions, uses fully defined
cGMP-ready components, and eliminates ill-defined factors
such as knockout serum replacement (KSR), Matrigel, or
mouse embryonic fibroblast feeders that were part of previ-
ous protocols (Dincer et al., 2013). The specific factors used
to trigger placode induction are based on signals shown
to specify placode development in vivo (Figure 1A). We
observed that exposure to moderate concentrations of
bone morphogenetic protein 4 (BMP4) efficiently induced
cranial placode cells that adopted by ‘‘default’’ a lens fate
(Figures S1A–S1C). These results are in agreement with pre-
vious efforts of inducing placode fate from hPSCs and withday 0 of differentiation (directly before switch to differentiation me
tiations. Numbers above day-11 data point indicate average raw ct v
(C) Immunofluorescence analysis comparing protein expression on day
431542; neuroectoderm). Scale bars, 50 mm.
See also Figure S1.
860 Stem Cell Reports j Vol. 6 j 858–872 j June 14, 2016data in thedevelopingchick embryo reporting a lensdefault
in the absence of fibroblast growth factor (FGF) signals
(Bailey et al., 2006; Leung et al., 2013). Temporal expression
analysis revealed the rapid loss of pluripotencymarkers and
induction of key placode genes such as SIX1, EYA1, and
DLX3/5 after 6 days of differentiation at both mRNA
(Figure 1B) and protein (Figure 1C) levels. Transcripts of
contaminating cell types such as SOX10 (neural crest),
SOX17 (endoderm), T/Brachyury (mesoderm), or MYOD
(myogenic lineages) were not induced under these condi-
tions (Figure 1B). Our previous study reported PAX3+ tri-
geminal placode as the ‘‘default’’ identity of hPSC-derived
placode cells (Dincer et al., 2013). Our current method,
using the defined placode induction conditions, shows
PAX6 rather than PAX3 expression (Figure 1C). To further
quantify the yield and selectivity of placode induction
and PAX6 expression, we used hESC genetic reporter lines
for SIX1::H2B-GFP, PAX6::H2B-GFP, SOX10::GFP (Chambers
et al., 2012; Mica et al., 2013). Flow analysis confirmed
robust induction of PAX6 and SIX1 without SOX10,
consistent with anterior cranial placode in the absence of
contaminating neural crest cells (Figures S1D and S1E).
Patterning of Anterior Pituitary from hPSC-Derived
Cranial Placode
The complex morphogenetic development of the pituitary
gland occurs during early embryonic stages (embryonic
day 10 [E10] in mouse and between embryonic weeks 4
and 8 in human). Both the anterior and intermediate lobes
of the pituitary gland are derived from oral ectoderm,
which corresponds to the pituitary placode while the pos-
terior pituitary gland develops from the neural ectoderm
(Figure 2A). Inductive tissue interactions as well as various
defined signaling pathways including FGFs, BMPs, and
Sonic hedgehog (SHH) are thought to be important for
proper gland development and hormonal subtype specifi-
cations in vivo (Zhu et al., 2007) (Figure 2A, upper panel).
Here we assessed the ability of these developmental path-
ways to induce pituitary identity (Figure 2A, lower panel).
Our data show that timed exposure to SHH, FGF8,
and FGF10 robustly induces gene expression associated
with anterior pituitary development including PITX1/2,
LHX3/4, HESX1, and SIX6 (Figure 2B). Where possible, we
confirmed expression at the protein level using antibodies
against PITX1, LHX3, HESX1, and SIX6 (Figure 2C). We
compared our cGMP-ready E8/E6-based induction protocol
with our published KSR-based PIP (Dincer et al., 2013). Todium) and plotted as mean ± SEM from four independent differen-
alues for better comparison.
11 of cranial placode induction protocol and LSB (LDN-193189/SB-
Figure 2. Pituitary Specification of Anterior Cranial Placode-Derived hPSCs
(A) Schematic representation of pituitary gland in vivo development and protocol for directed differentiation of hPSCs into anterior
pituitary-like cells. ICM/Epibl., inner cell mass/epiblast; NNE, non-neural ectoderm.
(B) Real-time PCR analysis comparing expression of key genes involved in pituitary development in LSB, pituitary condition, and medium
conditioned by hypothalamic neuroectoderm (Hypothalamus CM) after 15 days of differentiation in the respective medium. Values are
normalized to GAPDH and gene expression on day 15 of lens differentiation (E6 only) and plotted as mean ± SEM of at least four inde-
pendent experiments. *p < 0.05, ***p < 0.001 compared with E6 only condition on day 15.
(C) Immunofluorescence analysis comparing expression of PITX1 and LHX3 after 15 days of differentiation under lens or pituitary con-
ditions as well as expression of HESX1 and SIX3/6 on day 15 of pituitary differentiation. Scale bars, 50 mm.
(D) Immunofluorescence comparison of cells differentiated for 15 days under either pituitary or hypothalamus condition. Cells were
stained for either FOXG1 (Pituitary) or NKX2.1 (Hypothalamus). Scale bars, 50 mm.
(E) qRT-PCR analysis of day 0-15 cells differentiated under pituitary or hypothalamic ectoderm condition probing for NKX2.1 and FOXG1.
Values have been normalized to GAPDH and expression in day-6 placode cells and are plotted as means ± SEM of two to four independent
experiments.
See also Figures S2 and S3.
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Figure 3. Pituitary Placode Induction from Purified SIX1:GFP-
H2B Cells
(A) Schematic representation of the experimental outline. hESC
were differentiated under default conditions for 6 days. Un-
patterned SIX1+ cells were FACS purified and cultured for an addi-
tional 9 days in various conditions. Cells were analyzed on day 15.
(B) Gene-expression analysis of key pituitary genes in cells grown
in three conditions described in (A). Values are normalized to
GAPDH and gene expression on day 15 of lens differentiation
(E6 only) and plotted as mean ± SEM of at least four independent
experiments. *p < 0.05, **p < 0.01 compared with E6-only condi-
tion on day 15.
(C) Immunofluorescence analysis of SIX1 sorted cells after 9 days
of differentiation in respective medium condition. Arrows indicate
absence of LHX3 expression in SIX1+ cells in co-culture condition.
Scale bars, 50 mm.
862 Stem Cell Reports j Vol. 6 j 858–872 j June 14, 2016compensate for KSR lot-to-lot variability, which can
dramatically affect differentiation efficiency, we performed
PIP using two distinct concentrations of the BMP inhibitor
LDN-193189. After 15 days of differentiation, the cells were
analyzed using qRT-PCR probing for pan-placodal markers
such as SIX1 as well as the pan-pituitary markers PITX1,
PITX2, LHX3, and LHX4. In addition, the neuroectoderm
marker PAX6 and the non-neural ectoderm transcription
factor TFAP2A were included in the analysis (Figure S2A).
Cell identity was further confirmed at the protein level us-
ing immunofluorescence staining for SIX1 and LHX3 (Fig-
ure S2B). The KSR lot used for these experiments failed to
effectively induce pituitary or placode identity as shown
by the low expression of SIX1 and TFAP2A and high
expression of PAX6. Lowering the LDN-193189 concen-
tration was able to partially but not fully rescue that effect
compared with our new E8/E6-based protocol. The cGMP-
ready protocol presented here works reliably and with
comparable efficiency across various hESC and hiPSC lines
(Figures S3A–S3C). Furthermore, we confirmed that the re-
combinant protein SHH can be replaced by small-molecule
smoothened agonists such as purmorphamine and SAG
(Figures S3D and S3E). However, despite robust induction
of anterior pituitary-lineage markers, we observed an in-
crease in cell death when using the small-molecule-based
induction conditions, which prompted us to use recombi-
nant SHH for subsequent studies.
Interestingly, medium conditioned by hPSC-derived hy-
pothalamic anlage (Maroof et al., 2013; Merkle et al., 2015)
(Figures 2D and 2E) was not sufficient to robustly induce
pituitary marker expression (such as LHX4, HESX1, and
SIX6; Figure 2B). LHX4 and SIX6 have been implicated
in pituitary progenitor expansion, which might explain
the reduced cell yield using hypothalamic-conditionedme-
dium. Despite compelling evidence to the contrary (Suga
et al., 2011), our data suggest that defined extrinsic cues
might be sufficient to induce pituitary placode identity.
To directly assess the role of hypothalamic tissue during
pituitary placode induction and differentiation, we made
use of the SIX1::H2B-GFP reporter cell line. Early placode
cells differentiated under default conditions were sorted
at day 6 of differentiation for SIX1::H2B-GFP expression fol-
lowed by further differentiation under either lens condi-
tions (default), in the presence of SHH, FGF8, and FGF10
(pituitary conditions) or in the presence of medium condi-
tioned by hPSC-derived hypothalamic neuroectoderm
(Figure 3A). Gene-expression analysis revealed that even
purified SIX1::H2B-GFP+ cells, devoid of any hypothalamic
lineage cells, are capable of expressing all key pituitary
markers in response to defined cues. In contrast, hypotha-
lamic conditioned medium failed to induce LHX4 expres-
sion above levels observed under default lens conditions
(Figure 3B). The levels of induction, especially LHX4,
were slightly lower in the SIX1::H2B-GFP purified cells
compared with our standard pituitary PIP. This is possibly
due to the relatively late pituitary induction, which started
on day 6 (versus day 4) to exclude patterning of the pre-pla-
code tissue. Alternatively, the sorting process or the associ-
ated cell dissociation may have also contributed to the
slight decrease in induction efficiency.
In a separate set of experiments, we co-cultured day-6
sorted, SIX1::H2B-GFP+ cells in direct contact with hPSC-
derived hypothalamic anlage and stained the cells for the
pan-placodal marker SIX1 and the pituitary marker LHX3
after 9 days of additional co-culture (day 15). As additional
controls, we included the ‘‘default’’ lens conditions as well
as our standard pituitary conditions and hypothalamic-
conditioned medium (Figure 3A). While the lens condi-
tion formed lentoid-like clusters and downregulated SIX1
expression, the pituitary condition resulted in SIX1/
LHX3 double-positive cells. The conditioned medium
maintained SIX1 while inducing only low levels of LHX3.
In the co-culture, SIX1 expression was maintained but no
LHX3 expression was detected (Figure 3C). These findings
support the idea that exposure to defined extrinsic cues is
sufficient to direct hPSC into pituitary lineages cells. While
we cannot rule out that further optimization of co-culture
conditions may yield pituitary-lineage cells, we demon-
strate that defined signals present a robust alternative
that during cell manufacturing should greatly reduce vari-
ability inherent to complex co-culture systems.
hPSC-Derived Adenohypophyseal Cells Are
Functional
Themain function of the anterior pituitary (adenohypoph-
ysis) is to secrete six specific hormones controlling key
events in the human body including stress response
(adrenocorticotropic hormone [ACTH]), skeletal growth
(growth hormone [GH]), metabolism (thyroid-stimulating
hormone [TSH]), and reproductive functions (prolactin
[PRL], follicle-stimulating hormone [FSH], luteinizing hor-
mone [LH]). We therefore assessed the presence of hor-
monal subtypes in our culture. We were able to detect
ACTH, GH, and PRL as well as FSH- and LH-expressing cells
in our culture at day 30 of differentiation (Figure 4A). ELISA
measurements of cell-culture supernatant confirmed basal
secretion rates for ACTH, GH, and FSH (Figure 4B). Hor-
mone release in the anterior pituitary gland is tightly regu-
lated by several feedback mechanisms from the various
target organs as well as from upstream hypothalamic sig-
nals delivered via the hypophyseal portal venous plexus.
Therefore, the functional response of pituitary cells must
integrate multiple, distinct regulatory stimuli. hPSC-
derived pituitary cells at day 30 of differentiation showed
induction of ACTH release in response to stimulation
with corticotropin-releasing factor (CRF), stressin, or uro-cortin. In contrast, exposure to inappropriate stimuli
such as ghrelin or somatocrinin did not trigger ACTH
release (Figure 4C). On the other hand, somatocrinin but
not CRF exposure triggered a significant increase in GH
release (Figure 4D). Finally, the cultures also induced FSH
release upon exposure to nafarelin (Figure 4E).
Single-Cell Gene-Expression Analysis Reveals
Diversity of Hormonal Lineages
Differentiation of the hormonal progenitor lineages within
the adenohypophysis (Tabar, 2011) is a tightly regulated
spatial and temporal process involving various patterning
events (Figure 2A). To address the diversity of progenitor
fates in our hPSC-based culture system, we performed
single-cell qRT-PCR analyses. We probed for 34 genes span-
ning pituitary development from undifferentiated PSCs
to mature hormone-producing cells. We also included
primers to survey for potential mesodermal or endodermal
contaminants such asT/Brachyury,MYOD, and SOX17. Prin-
cipal component analysis (PCA) of cells at day30 andday60
of differentiation showed a clear time-dependent change in
expression with only few cells moving ahead of schedule
(i.e., day-30 cells showing a day-60 profile) or being delayed
(i.e., day-60 cells retaining a day-30 signature) (Figure 5A).
The scree plot (Figure 5B) defined the PCA components
that explainmost of the variability of the data. Hierarchical
clustering confirmed the separationof cells largely along the
time axis, resulting in two main clusters interspersed with
several smaller subclusters (Figure 5C). In addition, heat-
maps based on the raw ct values are provided in Figure S4.
We further validated our single-cell data by immunofluores-
cence staining in day-30 cultures for the progenitor marker
HESX1, and for NEUROD1, a more mature marker tran-
siently expressed in corticotrophs. Immunofluorescence
analysis at day 15 of differentiation served as negative con-
trol for NEUROD1 (Figure S5A). We confirmed co-labeling
of HESX1 andNEUROD1 in the same cell at day 30 of differ-
entiation. However, the levels of HESX1 expression were
much lower at day 30 compared with day 15.
Our analysis revealed that day-30 cultures contain an
already high percentage of pituitary-like cells with 70%
of cells co-expressing pituitary transcripts such as PITX1
and LHX3. Only four cells (5% of all cells analyzed) ex-
pressed T, SOX17, or MYOD, suggesting a low percentage
of contaminating cells. Most cells expressed TBX19
(TPIT) a transcription factor shown to be crucial for the
development of the POMC lineage (Lamolet et al., 2001).
Furthermore, most cells expressed the pan-placodal marker
SIX1 and co-expressed PAX6 compatible with pituitary
placode fate. However, we also observed expression of
other placode fates including PAX2 (epibranchial), PAX3
(trigeminal), or PAX8 (otic) that together were detected in
about 20% of the SIX1+ population.Stem Cell Reports j Vol. 6 j 858–872 j June 14, 2016 863
Figure 4. Functional Characterization of Anterior Pituitary Cells
(A) Immunofluorescence analysis of anterior pituitary cells after 30 days of differentiation. On day 30 the culture contains corticotrophs
(ACTH), somatotrophs (GH), and gonadotrophs (FSH, LH). Scale bar, 50 mm.
(B) In vitro basal hormone release on day 30 of differentiation as assessed by ELISA. Data are plotted as mean ± SEM of three independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with no cells (differentiation medium only).
(C–E) Quantification of hormone levels after 24 hr of in vitro stimulation using compounds triggering hormone release. ACTH release was
specifically induced by CRF, stressin, or urocortin and not by somatocrinin or ghrelin (C), GH release was induced by somatocrinin but
not CRF (D), and FSH release was induced by nafarelin (E). Data are plotted as mean ± SEM of three independent experiments. *p < 0.05,
**p < 0.01 compared with the solvent control.The ultimate functional units of the anterior pituitary are
cells that secrete specific hormones. Our single-cell analysis
showed that at day 30 of differentiation approximately
50% of the cells expressed at least one hormonal mRNA
species. This percentage increased to about 80% by day
60, indicating further in vitro maturation (Figure 5D).
This increase in the percentage of hormone-positive cells
was one of the main factors responsible for the overall dif-
ference observed between day-30 and day-60 cells. There
have been reports suggesting that both the developing
and adult rodent pituitary gland contain cells that express
more than a single hormone (Nunez et al., 2003; Villalobos
et al., 2004). Indeed, in our hPSC-derived cultures we could
detect expression of more than one hormonal transcript
(hereafter termed ‘‘multiple hormone transcripts’’) in
10% of the cells by day 30 of differentiation. By day 60 of
differentiation, this percentage increased to 30% of the
total cell population (Figure 5D). We found that the major-
ity of multiple hormone transcript-expressing cells by day864 Stem Cell Reports j Vol. 6 j 858–872 j June 14, 201660 expressed both POMC and GH (10%). Cells expressing
more than two hormone transcript types were only de-
tected by day 60 and always included POMC expression
(Figure S5B).
The most frequent hormonal transcript expressed in
hPSC-derived pituitary cells at day 30 of differentiation
was POMC (30% of total cells), thought to emerge from
the dorsal pituitary anlage. The more ventral cell types
such asGH or TSHmade up about 20% of the total cell pop-
ulation by day 30 of differentiation. PRL was expressed in
an even smaller subset of cells. Finally, FSH and LH, the
two most ventral cell types, which appear only at later
stages of development, were not detected by day 30
(Figure 5E). At day 60 of differentiation the number of
POMC- and GH-expressing cells increased to 55% and
30%, respectively. Only few cells expressed FSH (4%)
and LH (3%), even at day 60 of differentiation (Figure 5E).
In addition to the single-cell PCR we characterized the
cell-surface marker expression of the day-30 culture using
Figure 5. Temporal Single-Cell qRT-PCR Analysis of Anterior Pituitary Development In Vitro
(A and B) Principal component analysis of single cells on day 30 (black) and day 60 (green) of differentiation reveals two distinct
populations of cells.
(C) Unsupervised hierarchical clustering of day-30 and day-60 cells using 34 different primer pairs identifies two clusters of cells with very
few leading cells (day-30 cells resembling day-60 cells) and cells lagging behind (day-60 cells still more closely resembling day-30 cells).
(D) Quantification of hormone-expressing cells on day 30 and day 60 as well as percentage of cells expressing more than one hormonal
transcript per cell.
(E) Expression of individual hormonal transcripts per single cell on day 30 and day 60, respectively.
See also Figures S4 and S5.
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the commercially available BD Lyoplate screening kit
(Figure S6).
Dorsal-Ventral Patterning of Anterior Pituitary Cells
In Vitro Using Patterning Factors
Hypopituitarism is a very diverse and complex disease. De-
pending on the cause of pituitary dysfunction, the type of
hormones affected can vary. For example, GH deficits are
commonly observed in patients with inborn genetic dis-
ease (van Gelderen and van der Hoog, 1981) but can also
occur in patients following radiation treatment (Sklar and
Constine, 1995). In contrast, lymphocytic hypophysitis,
an autoimmune disease of the pituitary gland, affects pri-
marily ACTH (Rivera, 2006). Therefore, for the broad appli-
cation of hPSC-derived pituitary cells in the future, cell
replacement therapymay need to be customized to the spe-
cific needs of a given patient population. Since our stan-
dard conditions mostly yield dorsal, ACTH+ cells, we asked
whether additional signals can be used to enhance the pro-
duction of more ventral cell types. It has been shown that
FGF8 and BMP2 signaling gradients play an important role
in dorsal-ventral patterning of the mouse pituitary gland
(Rosenfeld et al., 2000) (Figure 2A). We therefore treated
pituitary-lineage cells with high concentrations of either
FGF8 (dorsalizing) or BMP2 (ventralizing), or with a
mixture of the two patterning factors at intermediate
concentrations to mimic morphogen gradients occurring
in vivo. Gene-expression studies for key transcription fac-
tors of pituitary precursor lineage and hormonal subtypes
confirmed the need for BMP2 to generate the most ventral
cell types. FSHB and LHB were significantly upregulated in
the presence of BMP2 while FGF8 exerted a negative effect
on FSHB yield (Figure 6A).
We next performed single-cell qRT-PCR analysis to in-
crease the resolution of our analysis. Unsupervised hierar-
chical clustering of single cells at day 60, treated with
FGF8, BMP2, or a combination of both factors, revealed
three larger clusters of cells (Figure 6B). In addition, heat-
maps based on the raw ct values are provided in Figure S4.
Cells corresponding to each of the three treatments were
observed in every cluster. However, 49% of all the total cells
in cluster 3were from the BMP2-treated groupwhile 56%of
all the cells in cluster 2 were derived from the FGF8 group.
Cluster 1 represented cells from all three treatments in
roughly equal proportions. By analyzing single-cell expres-
sion for each of the anterior pituitary hormones, we
confirmed findings predicted from mouse in vivo studies
(Rosenfeld et al., 2000) in our hPSC-based culture system.
High concentrations of FGF8 led to increased numbers of
POMC+ cells compared with high concentrations of BMP2
(75% versus 40%, respectively) (Figure 6C). Furthermore,
intermediate concentrations of both signaling molecules
resulted in an increase of cells expressing GH and TSHB866 Stem Cell Reports j Vol. 6 j 858–872 j June 14, 2016compared with either FGF8 or BMP2 alone (Figure 6C).
Finally, high concentrations of BMP2 decreased the num-
ber of POMC+ dorsal cell types and increased the number
of ventral FSHB and LHB cell types.
Immunofluorescence confirmed the single-cell qRT-PCR
data for four hormones under the various dorsal-ventral
patterning conditions (FGF8, FGF8/BMP2, BMP2; Fig-
ure 6D). Quantification showed a bias toward dorsal
ACTH (POMC)-expressing cells in the FGF8 treated culture.
PRL and GH were the most abundant hormones observed
upon patterning with FGF8/BMP2 while FSH was the
most abundant cell type in BMP2-treated cultures (Fig-
ure 6E). POMC is the precursor polypeptide of ACTH
and 44 amino acids are removed during translation, which
ultimately gives rise to the hormone ACTH.
Grafted Human ESC-Derived Anterior Pituitary Cells
Function in a Model of Hypopituitarism
To assess the ability of hPSC-derived pituitary cells to sur-
vive and function in vivo, we transplanted day-30 cells
into hypophysectomized rats. After surgical removal of
the pituitary gland (Figure 7A) using a parapharyngeal
approach, hypopituitarism in the rats was confirmed by
measuring ACTH levels in the plasma via ELISA. Rats that
were successfully hypophysectomized were divided into
two experimental groups, the sham group (n = 4) receiving
Matrigel-only injections and the grafting group (n = 7)
receiving Matrigel containing hESC-derived pituitary cells
(day 30, standard conditions without BMP2 treatment).
Following transplantation of 2 3 106 cells subcutaneously,
both treatment and control groups were followed for
7 weeks post-transplantation and pituitary hormone levels
in the plasma were monitored (Figures 7B–7D). At 3 weeks
after transplantation, hormone levels in the grafted group
increased compared with the 1-week time point while the
levels in the sham group remained largely unchanged.
ACTH levels remained at higher levels in the grafted versus
control group for the 7-week period of the experiment (Fig-
ure 7B). Increases in the level of two other hormones,
namely GH and LH, were more variable and did not reach
significance at all the time points tested. However, signifi-
cant increases in GH levels were detected at 3 and 7 weeks
after transplantation (Figure 7C). No significant increase in
LH levels was observed (Figure 7D). Hormone levels in
grafted animals were compared with levels in intact age-
matched rats and found to be 40% for ACTH, 28% for
GH, and 20% for PRL (Figure S7). In a final step to eval-
uate the function of the transplanted cells, we performed
measurements of the target hormones affected by pituitary
hormone secretion. The normal HPA-axis response in-
volves an increase in glucocorticoids secreted by the adre-
nal glands upon release of ACTH (Webster and Sternberg,
2004). In humans, ACTH triggers the release of cortisol,
Figure 6. Specification of Hormonal Cells
of the Pituitary In Vitro
(A) Bulk qRT-PCR analysis of day-60 cells
patterned with FGF8, FGF8/BMP2, or BMP2
for 30 days. Patterning with BMP2 induced
a more ventral cell identity (PIT1, GATA2,
GH1, FSHB, and LHB) while FGF8 suppressed
ventral cell types (FSHB). Data are plotted as
mean ± SEM of two to four independent
experiments. *p < 0.05, **p < 0.01, ***p <
0.001 (n.s., not significant) compared with
the ‘‘default’’ pituitary differentiation on
day 60.
(B) Unsupervised hierarchical clustering of
FGF8, FGF8/BMP2, and BMP2 patterned cells
using 34 primer pairs identified three larger
clusters of cells, with cluster 2 mainly com-
prising cells patterned by FGF8 (or FGF8/
BMP2) and cluster 3 mainly comprising cells
patterned by BMP2 (or FGF8/BMP2).
(C) Quantification of hormonal transcripts
per cell in different patterning conditions.
Data are plotted as percentage of cells ex-
pressing the respective transcript (ct < 35
cycles in combination with a proper melting
curve).
(D) Immunofluorescence analysis (represen-
tative images) of hormone expression in cells
patternedwith FGF8, FGF8/BMP2, or BMP2 on
day 60 of differentiation. Scale bars, 50 mm.
(E) Quantification of hormone-expressing
cells (per subtype) in different patterning
conditions on day 60 of differentiation.
High levels of FGF8 induced dorsal fate
(ACTH) while intermediate levels of FGF8
and BMP2 induced dorsal/ventral fates
(PRL and GH) compared with the default
condition (E6 only). Data are plotted as
mean ± SEM of two independent experi-
ments. *p < 0.05, **p < 0.01 (n.s., not
significant) compared with the ‘‘default’’ (E6
only) pituitary differentiation on day 60.
See also Figure S4.whereas the main glucocorticoid in rodents is corticoste-
rone (Wand, 2008). We therefore measured corticosterone
levels in both experimental groups (Figure 7E). The grafted
group showed consistently higher levels of corticosterone
than sham-grafted animals resulting in a statistically signif-
icant difference by 7 weeks after transplantation. These
data indicate an appropriate response by the host adrenal
glands to human ACTH released by grafted hPSC-derived
cells. At 7 weeks after transplantation, the animals were
euthanized and the graft was analyzed histologically. We
were able to detect cells expressing each of the six anteriorpituitary hormones within the grafts (Figures 7F and 7G),
confirming cell survival and suggesting, at least in part,
further in vivo differentiation and maturation of the cells.
Stereological quantification of the grafts showed an average
of 3.08 3 106 ± 0.42 3 106 (average ± SD; n = 3) human
cells per graft, with the majority (>95%) having a placode
identity, as determined by co-expression of SIX1 and hu-
man nuclear antigen (hNA) by immunohistochemistry.
The proportion of Ki67-positive proliferating cells in
the graft was 9.6% ± 0.6% (average ± SD; n = 3) of the
hNA+ population. The entire graft stained negative forStem Cell Reports j Vol. 6 j 858–872 j June 14, 2016 867
Figure 7. In Vivo Survival and Function of
hPSC-Derived Anterior Pituitary Cells
(A) Schematic representation of experi-
mental layout. After surgical removal of the
pituitary gland and confirmation of hypo-
pituitarism, cells embedded in Matrigel were
transplanted subcutaneously.
(B–E) ACTH (B), GH (C), LH (D), and corti-
costerone (E) levelswere quantified inplasma
for up to 7 weeks after transplantation of the
cells using ELISA. Data are plotted as mean ±
SEM with each dot representing an individual
animal. *p < 0.05, **p < 0.01 compared with
the corresponding sham control.
(F) Immunohistological analysis of grafts
7 weeks after transplantation. Cells of each
of the six hormonal lineages of the anterior
pituitary gland were detectable within the
graft. Scale bars, 50 mm.
(G) Quantification of cells expressing ACTH
and the corresponding graft volume 7 weeks
after transplantation. Data are plotted as
mean ± SEM with each dot representing an
individual animal (three animals in total).
See also Figure S7.the pluripotency-associated surface markers SSEA-4 and
Tra1-60. No signs of tumors were detected up to 7 weeks
after transplantation. Stereological analyses showed an
average of 18,212 ± 2,969 ACTH+ cells per animal (optical
fractionator method), and a graft volume of 81 ± 10 mm3
(Cavalieri estimator; average ± SD, n = 3).
DISCUSSION
A goal of our study was the development of a defined and
highly efficient protocol to generate anterior pituitary868 Stem Cell Reports j Vol. 6 j 858–872 j June 14, 2016lineages that obviates the need for co-culture or complex
media formulations and that should be suitable for clin-
ical-grade cellmanufacturing. Using fluorescence-activated
cell sorting (FACS)-purified SIX1::H2B-GFP+ placode cells,
we demonstrate that pituitary fate can be induced at the
expense of the default lens fate upon exposure to SHH,
FGF8, and FGF10. Under these conditions, induction oc-
curs in the absence of any hypothalamic cells previously
thought to be critical for pituitary specification. While
the signals essential for pituitary cell-fate induction from
hPSCs do not require the presence of hypothalamic lineage
cells, the interactionwith the hypothalamic anlage is likely
important for the complex tissuemovements characteristic
of pituitary gland development such as the formation of
the Rathke’s pouch. In future studies it may be interesting
to combine directed differentiation and organoid culture
techniques to study developmental tissue interactions
and to retain 3D cytoarchitecture. However, our current
strategy offers obvious advantages for cell manufacturing
of highly defined, therapeutically relevant cell types at
scale. The cGMP-ready PIP presented here has severalmajor
advantages over the previously published protocol (Dincer
et al., 2013). It is well established that KSR can exhibit
considerable lot-to-lot variability (Rao, 2008; Schwartz
et al., 2011). The protocol presented here overcomes these
challenges and yields improved overall differentiation
efficiencies under conditions of minimal lot-to-lot vari-
ability based on testing >10 different lots of Essential8
for hiPSC maintenance and >5 different lots of Essential6
for differentiation.
Our studymadeuse of single-cell transcriptional profiling
to define the heterogeneity of hormone-producing cells
derived from hPSCs. The technology is a powerful tool
that allowed us to determine the percentage of various hor-
mone-producing cells and shifts in this distribution upon
treatment with patterning factors or comparing different
time points in vitro. However, one of the challenges of sin-
gle-cell profiling is the largely binary readout of the expres-
sion data (McDavid et al., 2013). The HESX1/NEUROD1
validation experiment exemplifies this drawback, as the
single-cell RT-PCR was not able to capture the decrease in
HESX1 expression over time as observed by immunocyto-
chemistry. Therefore, our binary approach of identifying
expressed genes leads to the possibility that lowly expressed
genesmay be read as positive despite their expression levels
not being high enough to achieve meaningful translation
into protein. For example, we observed some instances of
‘‘inappropriate’’ expression patterns such as the co-expres-
sion of SIX1 with PAX6 and PAX3 (though at different
expression levels), which would indicate a mixed regional
cranial placode identity. Similarly, the presence of putative
plurihormonal cells was based purely on the expression of
multiple hormonal transcripts. The presence of plurihor-
monal cells in the pituitary gland has been reported previ-
ously (Nunez et al., 2003; Villalobos et al., 2004) and is
a well-known feature in pituitary adenomas (Scheithauer
et al., 1986). However, it will be important to further assess
in hPSC-derived pituitary cells whether transcripts for mul-
tiple hormones indeed result in the expression and secre-
tion of multiple hormones from individual cells. To resolve
some of the limitations of the single-cell gene-expression
study, it will be important in the future to obtain appro-
priate positive and negative controls in order to define
tissue-relevant thresholds of expression for each transcript.Unfortunately, developmentally matched human tissues
are not readily available. In the present study we used
immunofluorescence analysis as an independent method
to quantify bona fide hormone-producing cells. Due to
the lower sensitivity of this assay compared with qRT-PCR
analysis, the percentages of hormone-positive cells were
found to be lower but with the same relative proportions
of the various hormone-producing cells.
We demonstrate that exposure to FGF8 and BMP2 can
bias the dorsal-ventral composition of hormone-producing
cells from ACTH+ cells to FSH+ or LH+ cells. It should be
noted that in vivo, cell types expressing different hor-
mones are not necessarily located in specific areas but are
scattered throughout the mature gland (Ericson et al.,
1998; Olson et al., 2006). In addition, some reports argue
for a less important role of extrinsic signaling compared
with intrinsic factors in pituitary cell specification (Davis
et al., 2011). Our human in vitro systemprovides a valuable
tool to answer such questions. The current differentiation
protocols only achieve partial enrichment of specific hor-
monal lineages. Therefore, lineage selection via cell sorting
or the development of more sophisticated patterning
strategies will be required to obtain purified populations
such as GH+ cells suitable for treating patients with selec-
tive GH deficiency (Bianchi et al., 2008). Our cell-surface
epitope screen presents candidatemarkers thatmay be suit-
able for isolating specific hormone lineages. One cell type
lacking in the current in vitro culture system are TSH+ cells.
Studies in sheep suggest that proper hypothalamic input is
required for the development of thyrotrophs (Szarek et al.,
2008). Therefore, it is conceivable that hypothalamic line-
age cells may still be required for generating TSH+ fates.
Alternatively, TSH+ cells may simply require further opti-
mization of our defined induction conditions or longer
in vitro differentiation periods.
The in vivo studies show clear evidence of survival and
hormone release up to 7 weeks after transplantation.
Whether the lower percentage of hormone-producing cells
in vivo is due to limited cell survival or increased prolifera-
tion of immature pituitary progenitors remains to be deter-
mined. Future studies also need to define the optimal
transplantation time point for in vivo yield and hormone
subtype and demonstrate the long-term survival of hPSC-
derived pituitary cells. One key question is whether the
functional integration of human cells will eventually
require orthotopic placement of the graft into the pituitary
gland or hypothalamic region. Preliminary experiments
with orthotopic (median eminence) placement of the cells
into lesioned animals resulted in low cell survival, suggest-
ing the need for further optimization of such a transplanta-
tion paradigm. Ectopic placement in accessible locations
does offer advantages from a translational perspective,
namely the ability to access and remove the graft, shouldStem Cell Reports j Vol. 6 j 858–872 j June 14, 2016 869
adverse side effects develop.However, hypothalamic release
factors are themain triggers forhormonal release in theante-
rior pituitary gland (Smith and Vale, 2006). These release
hormones have a short half-life and do not persist in the cir-
culation. They are released into the hypophyseal portal
venous plexus, which ensures immediate local delivery to
the gland. Thus it is likely that the ectopically placed
hPSC-derived grafts did not gain significant exposure to hy-
pothalamic input. Our data therefore suggest a degree of
autonomoushormonal release by thegrafted cells, although
a more comprehensive assessment of integration into ho-
meostatic, endocrine mechanisms will be necessary. Based
on existing literature on grafting primary cells (Maxwell
et al., 1998; Naik et al., 1997), it is likely that proper regula-
tion of at least some of the pituitary hormones will require
orthotopic placement. Direct access to the skull base and
pituitary gland in themouse requires aggressive surgicalpro-
cedures, such as transaural approaches or parapharyngeal
neckdissection, complicating suchstudies.This is inmarked
contrast to human patients in whom surgical access to the
pituitary gland can be safely performed through minimally
invasive endoscopic transnasal routes (Tabar, 2011).
In conclusion, our study offers systematic access to hu-
man pituitary cell development and represents a powerful
tool to obtain diverse hormone-producing cell types on
demand and at scale. The platform also presents an impor-
tant proof of concept in establishing functional and
engraftable hormone-producing cells for regenerativemed-
icine under conditions suitable for preclinical and clinical
development.EXPERIMENTAL PROCEDURES
Human Pluripotent Stem Cell Culture and
Differentiation
The four hPSC lines (three hESC, one hiPSC) used in this study
were maintained under feeder-free conditions using Essential8
and VTN-N. Cells were passaged twice a week using EDTA. All
the differentiations carried out in this study are described in detail
in Supplemental Experimental Procedures.Phenotypic Characterization of Differentiated Cells
hPSC-derived cell types were characterized using immunofluores-
cence, qRT-PCR, flow cytometry, high content surface marker
phenotyping (BD Lyoplate), and single hormone as well as multi-
plex ELISA. Details, including all antibodies used in this study, are
described in Supplemental Experimental Procedures.Single-Cell qRT-PCR
FACS-sorted single cells were captured using the C1 System (Fluid-
igm). Single-cell qRT-PCR was performed using wet-lab tested
DELTAgene Assays (Fluidigm) in combination with EvaGreen
chemistry using a BioMark System (Fluidigm). A complete list of870 Stem Cell Reports j Vol. 6 j 858–872 j June 14, 2016primers used for this study is provided in Supplemental Experi-
mental Procedures.Animal Maintenance
The Animal Care and Use Committee at Memorial Sloan Kettering
Cancer Center approved all animal protocols. All procedures were
performed in accordance with NIH guidelines.Statistical Analysis
All data are presented as mean ± SEM. The number of independent
biological experiments performed for each analysis is indicated in
the respective figure legend. Unpaired t test or one-way ANOVA
with Bonferroni multiple-comparison post hoc test was used to
assess significance levels. Significance levels were set at *p < 0.05,
**p < 0.01, ***p < 0.001, and ***p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and two tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2016.
05.005.
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